...
首页> 外文期刊>Biologicals: Journal of the International Association of Biological Standardization >Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70.
【24h】

Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70.

机译:基于ESAT-6和HSP70截短的C末端片段的结核分枝杆菌新型融合蛋白的克隆,表达和免疫原性。

获取原文
获取原文并翻译 | 示例
           

摘要

Tuberculosis (TB) remains as a major public health problem worldwide. Identification and selection of immunodominant antigens of Mycobacterium tuberculosis (MTB), capable of efficiently inducing a protective immune response is the ultimate goal of TB vaccine development studies. Accordingly, this study was designed to produce a novel M. tuberculosis fusion protein consisted of MTB ESAT-6 (early secreted antigenic target-6 kDa), as a potent immunogenic protein, fused to C-terminus of MTB HSP70 (HSP70(359-610)), as an appropriate carrier and adjuvant. The constructed gene was inserted into a prokaryotic expression vector (pQE30); consequently, the recombinant fusion protein with a 6xHis-tag was successfully over expressed in Escherichia coli M15. Inclusion bodies from bacterial cell lysates were solubilized and the recombinant fusion protein was easily purified by Ni-NTA affinity chromatography under denaturing conditions followed by urea gradient dialysis. The purified and refolded protein was then applied for immunization of mice that resulted in the detection of high titers of specific antibodies, high level of IFN-gamma and cell proliferation. The results of our study could confirm the capability of E6H70C fusion protein, as a potential tuberculosis vaccine candidate, for the efficient induction of specific immune responses in a mouse model. However, further investigation need to evaluate the protectivity of this recombinant protein in host model.
机译:结核病(TB)仍然是世界范围内的主要公共卫生问题。能够有效诱导保护性免疫应答的结核分枝杆菌(MTB)免疫优势抗原的鉴定和选择是结核病疫苗开发研究的最终目标。因此,本研究旨在生产一种新型的结核分枝杆菌融合蛋白,该蛋白由有效的免疫原性蛋白MTB ESAT-6(早期分泌的抗原靶标6 kDa)组成,与MTB HSP70(HSP70(359- 610)),作为合适的载体和佐剂。将构建的基因插入原核表达载体(pQE30);因此,具有6xHis标签的重组融合蛋白在大肠杆菌M15中成功地过表达。来自细菌细胞裂解物的包涵体被溶解并且重组融合蛋白易于通过变性条件下的Ni-NTA亲和色谱纯化,然后进行尿素梯度透析。然后将纯化并重新折叠的蛋白质用于小鼠免疫,从而检测到高滴度的特异性抗体,高水平的IFN-γ和细胞增殖。我们的研究结果可以证实E6H70C融合蛋白作为潜在的肺结核疫苗候选物在小鼠模型中有效诱导特异性免疫应答的能力。然而,进一步的研究需要评估该重组蛋白在宿主模型中的保护性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号